Skip to content

Executive Summary

About this guideline

Summary of Clinical Practice Guidelines

Assessment for Anaemia of CKD (Guidelines 1.1 – 1.5)

Treatment of Anaemia of CKD with Iron (Guidelines 2.1 – 2.7)

Treatment of Anaemia with Erythropoiesis Stimulating Agents (Guidelines 3.1 – 3.17)

Treatment of Anaemia with HIF-PHI Agents (Guidelines 4.1 – 4.9)

Treatment of Anaemia of CKD with Blood Transfusions (Guidelines 5.1 – 5.1.3)

Management of Peri-Transplant and Post-Transplant Anaemia (Guidelines 6.1 – 6.3.3)

Special Populations (Guidelines 7.1 – 7.3)

Summary of Audit Measures on Anaemia of CKD

Summary of Research Recommendations

Rationale for Clinical Practice Guidance

New Therapies for Consideration in the Future

Patient Information Leaflet for Anaemia of CKD

Anaemia of CKD Guideline

Guidelines Library

Linkedin Instagram Youtube Facebook

2023 Update: Summary of changes to Recommendations

Summary of Recommendations

Section 1: Background, aims and concise methods

1.2 Introduction

1.3 Molecular Mechanisms Of Action Of SGLT2IÂ Inhibition

1.5 Guideline Aims & Development

Section 2: SGLT 2 inhibition and kidney protection in people with CKD in the context of type 2 diabetes mellitus

2.2 Recommendations For Use

2.3 Clinical Research Recommendations

2.4 Recommendations For Implementation

2.5 Audit Measures

Section 3: SGLT 2 inhibition and kidney protection in people with CKD without diabetes mellitus

3.2 Recommendations For Use

3.3 Clinical Research Recommendations

3.4 Recommendations for Implementation

3.5 Audit Measures

Section 4: Selection of SGLT 2 inhibitors

4.2 Current Licensed Indications for SGLT 2 Inhibitor Use

Section 5: Prescribing SGLT 2 inhibitors safely

5a. Diabetic ketoacidosis

5b. Hypoglycaemia

5c. Acute Kidney Injury, Hypovolaemia and Potassium

5d. Peripheral vascular disease and amputation risk

5e. Fracture risk

5f. Multimorbidity and frailty

5g. Mycotic genital infections and Fournier’s gangrene

5h. Urinary tract infections

5i. Children, pregnancy and breast feeding

Section 6: Lay summaries and patient information leaflets

6.1 Lay Executive Summary

6.2 Full Summary of Guideline

6.3 Example Patient Information Sheet for a Person being Initiated on an SGLT 2 Inhibitor who also has Diabetes

6.4 Example Patient Information Sheet for a Patient being Initiated on an SGLT 2 Inhibitor who does not have Diabetes

Section 7: Use in special populations of specific interest

7a. Type 1 diabetes mellitus (DM)

7b. Kidney transplant recipients

7c. Acute decompensated heart failure

List of Abbreviations

Appendix I: Systematic literature review design and results

Appendix II: Revision history

Appendix III: Working group membership affiliations

Guidelines Library

Search Everything...

Navigate to sections

Executive Summary

About this guideline

Summary of Clinical Practice Guidelines

Assessment for Anaemia of CKD (Guidelines 1.1 – 1.5)

Treatment of Anaemia of CKD with Iron (Guidelines 2.1 – 2.7)

Treatment of Anaemia with Erythropoiesis Stimulating Agents (Guidelines 3.1 – 3.17)

Treatment of Anaemia with HIF-PHI Agents (Guidelines 4.1 – 4.9)

Treatment of Anaemia of CKD with Blood Transfusions (Guidelines 5.1 – 5.1.3)

Management of Peri-Transplant and Post-Transplant Anaemia (Guidelines 6.1 – 6.3.3)

Special Populations (Guidelines 7.1 – 7.3)

Summary of Audit Measures on Anaemia of CKD

Summary of Research Recommendations

Rationale for Clinical Practice Guidance

New Therapies for Consideration in the Future

Patient Information Leaflet for Anaemia of CKD

Anaemia of CKD Guideline

Guidelines Library

2023 Update: Summary of changes to Recommendations
Executive Summary
- Quick Reference Guide
Section 1: Background, aims and concise methods
Section 2: SGLT 2 inhibition and renal protection in people with CKD in the context of type 2 diabetes mellitus
Section 3: SGLT 2 inhibition and renal protection in people with CKD without diabetes mellitus
Section 4: Selection of SGLT 2 inhibitors
Section 5: Prescribing SGLT 2 inhibitors safely
Section 6: Lay summaries and patient information leaflets
Section 7: Use in special populations of specific interest
Appendix

Sodium Glucose Co transporter 2

Section 6: Lay summaries and patient information leaflets

Section 6: Lay summaries and patient information leaflets

6.0 Background

6.1 Lay Executive Summary

6.2 Full Summary of Guideline

6.2.1 Introduction
6.2.2 SGLT-2 inhibitors: what are they?
6.2.3 Benefits of SGLT-2 inhibitors
6.2.4 How this guideline was developed
6.2.5 Benefits of SGLT-2 inhibitors: cardiovascular benefits
6.2.6 Benefits of SGLT-2 inhibitors: kidney protection
6.2.7 Separation of glucose from cardiac and kidney benefit
6.2.8 Identifying individuals where there is benefit in prescribing SGLT 2 inhibitors
6.2.9 Groups where there is uncertainty
6.2.10 Side effects of SGLT-2 inhibitors and how to avoid them
6.2.11 Diabetes specific: diabetic ketoacidosis
6.2.12 Diabetes specific: Low blood glucose or hypoglycaemia
6.2.13 Acute kidney injury
6.2.14 Dehydration issues
6.2.15 Peripheral vascular disease
6.2.16 Bone Health
6.2.17 Fungal genital infections (i.e. thrush)
6.2.18 Fournier’s gangrene
6.2.19 Urinary infections
6.2.20 Special populations: Children, pregnancy and breastfeeding

6.3 Example Patient Information Sheet for a Person being Initiated on an SGLT 2 Inhibitor who also has Diabetes

6.4 Example Patient Information Sheet for a Person being Initiated on an SGLT 2 Inhibitor who does not have Diabetes

2026 The UK Kidney Association. All rights reserved